A 52-year-old man with type 2 diabetes mellitus is enrolled in a randomized controlled trial comparing a new antidiabetic agent (Drug X) versus standard metformin therapy for glycemic control over 12 weeks. The trial protocol specifies that participants are assigned to treatment groups using a computer-generated random sequence, and neither the participants nor the outcome assessors know which treatment each patient receives. At week 6, the data safety monitoring board (DSMB) performs an interim analysis and finds that Drug X shows a statistically significant 2% reduction in HbA1c compared to metformin (p = 0.02). The DSMB recommends continuing the trial to completion as planned. Which of the following best explains why the trial was NOT terminated early despite the interim finding?

Question

Accepted Answer

A. A single interim analysis with a pre-specified stopping boundary (alpha-spending function) had not yet been crossed, and the clinical difference, though statistically significant, was modest and required confirmation at trial completion. ## RCT Interim Analysis and Early Stopping Rules

**Key Point:** Interim analyses in RCTs are pre-planned, not ad-hoc. They use pre-specified stopping boundaries (alpha-spending functions) to control the overall Type I error rate when multiple looks at the data occur.

### Why the Trial Continued

1. **Pre-specified Stopping Boundaries**
   - RCTs that include interim analyses must define stopping rules *before* the trial begins
   - These rules use alpha-spending functions (e.g., O'Brien-Fleming, Pocock) to allocate the total significance level across interim and final analyses
   - A single interim p-value of 0.02 does NOT automatically trigger early termination

2. **Clinical vs. Statistical Significance**
   - A 2% HbA1c reduction, while statistically significant, represents a modest clinical benefit
   - Interim analyses are designed to stop early only if:
     - The effect size is **large and unequivocal** (crosses the pre-specified efficacy boundary), OR
     - **Futility** is demonstrated (the treatment is unlikely to show benefit by trial end)
   - This finding met neither threshold

3. **Confirmation Principle**
   - A single interim result, even if significant, requires confirmation at the final analysis
   - Continuing to the planned sample size strengthens the evidence base

**High-Yield:** The **alpha-spending approach** (Lan-DeMets) allows multiple interim looks while preserving the overall Type I error rate. Common boundaries:

| Boundary Type | Characteristic | Use Case |
| --- | --- | --- |
| O'Brien-Fleming | Stringent early, lenient late | Prefer early stopping only for large effects |
| Pocock | Uniform across looks | Balanced early/late stopping |

**Clinical Pearl:** DSMB decisions to continue are as important as early stopping decisions. Continuing a trial that shows modest interim benefit confirms the finding is robust and clinically meaningful.

**Mnemonic: STOP-IT** — Stopping rules in RCTs require:
- **S**tatistical boundary (pre-specified alpha level for interim)
- **T**rue efficacy or futility (large effect or no hope)
- **O**verall error rate control (alpha-spending)
- **P**re-planned (not post-hoc)
- **I**nterim analysis protocol (written before trial starts)
- **T**iming (interim looks scheduled in advance)

[cite:Park 26e Ch 10]

Answer

B. The p-value of 0.02 is not statistically significant because it exceeds the pre-specified alpha level for interim analysis

Answer

C. The sample size at interim analysis was too small to detect a clinically meaningful difference, and the trial required enrollment of all planned participants regardless of interim results

Answer

D. Interim analyses are never permitted in randomized controlled trials as they compromise blinding and introduce bias

Explanation

Practice similar questions